Investment House LLC increased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 0.5% during the second quarter, Holdings Channel reports. The fund owned 48,686 shares of the medical research company’s stock after buying an additional 223 shares during the period. Amgen accounts for 1.2% of Investment House LLC’s investment portfolio, making the stock its 24th largest position. Investment House LLC’s holdings in Amgen were worth $7,408,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Wellington Management Group LLP boosted its position in Amgen by 16.0% in the first quarter. Wellington Management Group LLP now owns 13,544,922 shares of the medical research company’s stock worth $2,030,789,000 after buying an additional 1,864,688 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Amgen by 2.1% in the first quarter. Geode Capital Management LLC now owns 6,444,273 shares of the medical research company’s stock worth $964,334,000 after buying an additional 132,632 shares during the last quarter. Nordea Investment Management AB raised its stake in shares of Amgen by 37.1% in the second quarter. Nordea Investment Management AB now owns 5,719,168 shares of the medical research company’s stock worth $870,171,000 after buying an additional 1,547,099 shares during the last quarter. UBS Asset Management Americas Inc. raised its stake in shares of Amgen by 12.4% in the first quarter. UBS Asset Management Americas Inc. now owns 3,712,647 shares of the medical research company’s stock worth $556,636,000 after buying an additional 409,863 shares during the last quarter. Finally, Legal & General Group Plc raised its stake in shares of Amgen by 1.0% in the first quarter. Legal & General Group Plc now owns 3,263,086 shares of the medical research company’s stock worth $489,239,000 after buying an additional 32,086 shares during the last quarter. 79.15% of the stock is owned by institutional investors.
Shares of Amgen Inc. (NASDAQ:AMGN) traded up 0.82% on Friday, reaching $166.81. The company’s stock had a trading volume of 3,999,620 shares. The stock has a market cap of $124.83 billion, a P/E ratio of 17.07 and a beta of 0.87. The firm’s 50 day moving average is $171.68 and its 200-day moving average is $161.02. Amgen Inc. has a 52-week low of $138.06 and a 52-week high of $176.85.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Wednesday, July 27th. The medical research company reported $2.84 EPS for the quarter, beating the Zacks’ consensus estimate of $2.74 by $0.10. Amgen had a return on equity of 29.30% and a net margin of 33.07%. The firm earned $5.69 billion during the quarter, compared to analysts’ expectations of $5.58 billion. During the same quarter last year, the firm posted $2.57 earnings per share. The company’s revenue for the quarter was up 5.9% compared to the same quarter last year. On average, equities research analysts forecast that Amgen Inc. will post $11.36 EPS for the current year.
The business also recently announced a quarterly dividend, which was paid on Thursday, September 8th. Stockholders of record on Wednesday, August 17th were issued a $1.00 dividend. The ex-dividend date was Monday, August 15th. This represents a $4.00 dividend on an annualized basis and a dividend yield of 2.40%. Amgen’s dividend payout ratio is presently 40.90%.
AMGN has been the subject of a number of research reports. BMO Capital Markets reiterated a “buy” rating and issued a $186.00 price objective on shares of Amgen in a research report on Tuesday, July 12th. Vetr upgraded Amgen from a “sell” rating to a “hold” rating and set a $165.78 price objective for the company in a research report on Wednesday, July 27th. Leerink Swann reiterated a “hold” rating on shares of Amgen in a research report on Saturday, September 17th. Zacks Investment Research lowered Amgen from a “buy” rating to a “hold” rating in a research report on Monday, August 1st. Finally, Goldman Sachs Group Inc. reiterated a “buy” rating and issued a $206.00 price objective (up from $204.00) on shares of Amgen in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $185.06.
In other news, VP Annette Louise Such sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 2nd. The stock was sold at an average price of $174.59, for a total value of $523,770.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 0.20% of the stock is owned by insiders.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.